Medincell S.A [MEDCL] vs Valneva SE [VLA] Detailed Stock Comparison
Medincell S.A
Euronext
Loading...
Valneva SE
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Medincell S.A wins in 4 metrics, Valneva SE wins in 10 metrics, with 0 ties. Valneva SE appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Medincell S.A | Valneva SE | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 70.64 | N/A |
| Price-to-Book Ratio | N/A | 2.82 | N/A |
| Debt-to-Equity Ratio | -3.59 | 120.48 | Medincell S.A |
| PEG Ratio | 79.00 | -8.69 | Valneva SE |
| EV/EBITDA | -46.64 | -4.07 | Medincell S.A |
| Profit Margin (TTM) | -66.50% | -43.21% | Valneva SE |
| Operating Margin (TTM) | -17.30% | -12.11% | Valneva SE |
| Return on Equity | 112.65% | -44.11% | Medincell S.A |
| Return on Assets (TTM) | -20.38% | -19.19% | Valneva SE |
| Free Cash Flow (TTM) | $17.81M | $-83.66M | Medincell S.A |
| 1-Year Return | 1.14% | 21.86% | Valneva SE |
| Price-to-Sales Ratio (TTM) | 18.85 | 2.94 | Valneva SE |
| Enterprise Value | $522.34M | $552.99M | Valneva SE |
| EV/Revenue Ratio | 20.45 | 2.97 | Valneva SE |
| Gross Profit Margin (TTM) | N/A | 53.20% | N/A |
| Revenue per Share (TTM) | N/A | $1 | N/A |
| Earnings per Share (Diluted) | $-0.62 | $-0.56 | Valneva SE |
| Beta (Stock Volatility) | 1.08 | 1.00 | Valneva SE |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Medincell S.A vs Valneva SE Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Medincell S.A | 0.44% | 0.63% | 1.14% | 3.10% | 6.39% | -8.89% |
| Valneva SE | 5.69% | 21.47% | 55.97% | 33.92% | 12.13% | 64.07% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Medincell S.A | 1.14% | 201.51% | 114.78% | 117.41% | 117.41% | 117.41% |
| Valneva SE | 21.86% | -62.51% | -28.63% | -1.81% | -26.69% | -26.69% |
Performance & Financial Health Analysis: Medincell S.A vs Valneva SE
| Metric | MEDCL | VLA |
|---|---|---|
| Market Information | ||
| Market Cap | €522.62M | €546.93M |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 108,896 | 1,256,916 |
| 90 Day Avg. Volume | 76,916 | 856,124 |
| Last Close | €15.98 | €3.79 |
| 52 Week Range | €12.00 - €19.00 | €1.73 - €4.24 |
| % from 52W High | -15.89% | -10.53% |
| All-Time High | €20.00 (Apr 06, 2020) | €29.70 (Nov 29, 2021) |
| % from All-Time High | -20.10% | -87.24% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 3.86% | 0.50% |
| Quarterly Earnings Growth | N/A | 0.50% |
| Financial Health | ||
| Profit Margin (TTM) | -0.67% | -0.43% |
| Operating Margin (TTM) | -0.17% | -0.12% |
| Return on Equity (TTM) | 1.13% | -0.44% |
| Debt to Equity (MRQ) | -3.59 | 120.48 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €-1.86 | €1.14 |
| Cash per Share (MRQ) | N/A | €0.99 |
| Operating Cash Flow (TTM) | €14.12M | €-46,934,000 |
| Levered Free Cash Flow (TTM) | €-18,438,000 | €-122,620,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Medincell S.A vs Valneva SE
| Metric | MEDCL | VLA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 70.64 |
| Forward P/E | 79.00 | -8.69 |
| PEG Ratio | 79.00 | -8.69 |
| Price to Sales (TTM) | 18.85 | 2.94 |
| Price to Book (MRQ) | N/A | 2.82 |
| Market Capitalization | ||
| Market Capitalization | €522.62M | €546.93M |
| Enterprise Value | €522.34M | €552.99M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 20.45 | 2.97 |
| Enterprise to EBITDA | -46.64 | -4.07 |
| Risk & Other Metrics | ||
| Beta | 1.08 | 1.00 |
| Book Value per Share (MRQ) | €-1.86 | €1.14 |
Financial Statements Comparison: Medincell S.A vs Valneva SE
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MEDCL | VLA |
|---|---|---|
| Revenue/Sales | N/A | €49.23M |
| Cost of Goods Sold | N/A | €23.04M |
| Gross Profit | N/A | €26.19M |
| Research & Development | N/A | €14.95M |
| Operating Income (EBIT) | N/A | €-5.96M |
| EBITDA | N/A | €-5.45M |
| Pre-Tax Income | N/A | €-7.76M |
| Income Tax | N/A | €1.47M |
| Net Income (Profit) | N/A | €-9.23M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MEDCL | VLA |
|---|---|---|
| Cash & Equivalents | €59.04M | €152.99M |
| Total Current Assets | €80.62M | €287.05M |
| Total Current Liabilities | €29.87M | €106.20M |
| Long-Term Debt | €51.46M | €188.74M |
| Total Shareholders Equity | €-16.37M | €175.25M |
| Retained Earnings | €-18.44M | €-573.16M |
| Property, Plant & Equipment | €7.80M | €154.31M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MEDCL | VLA |
|---|---|---|
| Operating Cash Flow | N/A | €-7.74M |
| Capital Expenditures | N/A | €-1.40M |
| Free Cash Flow | N/A | €-9.62M |
| Debt Repayment | N/A | €-685,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MEDCL | VLA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 108,896 | 1,256,916 |
| Average Daily Volume (90 Day) | 76,916 | 856,124 |
| Shares Outstanding | 33.06M | 162.40M |
| Float Shares | N/A | 116.85M |
| % Held by Insiders | 0.39% | 0.12% |
| % Held by Institutions | 0.31% | 0.24% |
Dividend Analysis & Yield Comparison: Medincell S.A vs Valneva SE
| Metric | MEDCL | VLA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |